PHM-Exch> 2010 Global report on surveillance and response: Multidrug and extensively drug-resistant TB (M/XDR-TB)

[Claudio Schuftan]

From: Ruggiero, Mrs. Ana Lucia (WDC) <ruglucia at paho.org>
crossposted from: EQUIDAD at listserv.paho.org


 *Multidrug and extensively drug-resistant TB (M/XDR-TB)
2010 Global report on surveillance and response

* *World Health Organization, 2010* *…..Drug-resistant tuberculosis now at
record levels….

* *Available online PDF [71p.]  at:
http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf

*

18 MARCH 2010 | GENEVA | WASHINGTON DC – “……In some areas of the world, one
in four people with tuberculosis (TB) becomes ill with a form of the disease
that can no longer be treated with standard drugs regimens, a World Health
Organization (WHO) report says.

For example, 28% of all people newly diagnosed with TB in one region of
north western Russia had the multidrug-resistant form of the disease
(MDR-TB) in 2008. This is the highest level ever reported to WHO.
Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in
2007.

In the new WHO's *Multidrug and Extensively Drug-Resistant Tuberculosis:
2010 Global Report on Surveillance and Response*, it is estimated that 440
000 people had MDR-TB worldwide in 2008 and that a third of them died. In
sheer numbers, Asia bears the brunt of the epidemic. Almost 50% of MDR-TB
cases worldwide are estimated to occur in China and India. In Africa,
estimates show 69 000 cases emerged, the vast majority of which went
undiagnosed…..”

*Content:*

Summary

Introduction

*Part I: Surveillance of M/XDR-TB *

1.1 Geographical coverage of anti-TB drug resistance data

1.2 Resistance to first-line anti-TB drugs, including MDR-TB

1.3 Risk factors for drug resistance: previous treatment, sex and HIV

1.4 Trends over time

1.5 Resistance to second-line anti-TB drugs, including XDR-TB

1.6 Estimated global burden of MDR-TB

*Part II: Progress in the global response to M/XDR-TB  *

2.1 Scaling up laboratory services for diagnosis of M/XDR-TB

2.2 Reporting of MDR-TB patients and their treatment outcomes

2.3 Addressing other health systems considerations for the response to
M/XDR-TB

2.4 Financing the care of drug-resistant TB patients in the 27 high MDR-TB
burden countries

References
Annexes
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20100319/8515d7c1/attachment-0001.html>